Kelonia data build confidence around in vivo CAR Ts at ASH 2025

Another in vivo CAR T therapy has produced early clinical proof of concept, adding momentum to a modality that has become one of the few bright spots in the slumping cell and gene therapy sector. The durability of responses — and the performance of a rapidly diversifying pipeline of next-gen technologies — will determine how far that momentum carries.

At the American Society of Hematology (ASH) annual meeting, Kelonia Therapeutics Inc. presented data showing that four heavily pretreated multiple myeloma patients achieved minimal residual disease negativity one month after infusion with KLN-1010, a lentiviral gene therapy that delivers a BCMA-directed CAR to T cells in vivo. ...